INDV's Sublocade reaches 500,000+ U.S. patients. Management expects faster 2026 growth through cost optimization and strong ...

Indivior develops buprenorphine-based treatments for opioid dependence, serving markets in the US, UK, and worldwide.

Indivior's relative strength line has bolted into new high ground.

Exclusive: Fears that US companies may withdraw more medicines as global markets react to policy changes by the Trump administration ...

According to its SEC filing dated May 15, 2026, Madison Avenue Partners opened a new position in Indivior (NASDAQ:INDV) during the first quarter by acquiring 4,315,162 shares. The estimated value of ...

Looking ahead to 2030, our model projects INDV could trade at an average price of $82.11, with a potential range between ...

On November 13, 2022, Indivior and Opiant entered into a definitive agreement under which Indivior would acquire Opiant for an upfront consideration of $20.00 per share, in cash (approximately $145 ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability ...

Short interest is currently not available. Nasdaq provides information of company’s short interest and the average days it takes to cover them. Short interest and days to cover can be used to indicate ...

Indivior PLC INVVY INDV published modeling data examining the competitive interaction between buprenorphine, a treatment for opioid use disorder, and fentanyl, a potent synthetic opioid, to better ...

Suboxone maker Indivior has spent years dealing with allegations related to its role in the United States opioid epidemic, inking several settlements over that span and even witnessing its former CEO ...

Indivior has snapped up Opiant Pharmaceuticals for an initial $145 million, capitalizing on the fall of the company’s share price throughout the year to add a near-approval nasal formulation of ...